Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
PTIE's Cash to Debt is ranked higher than
95% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. PTIE: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PTIE' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Interest Coverage No Debt
PTIE's Interest Coverage is ranked higher than
94% of the 458 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PTIE: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PTIE' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 2
Z-Score: -2.89
M-Score: -4.13
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -64.29
PTIE's ROE (%) is ranked lower than
69% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. PTIE: -64.29 )
Ranked among companies with meaningful ROE (%) only.
PTIE' s ROE (%) Range Over the Past 10 Years
Min: -64.29  Med: -5.01 Max: 102.69
Current: -64.29
-64.29
102.69
ROA (%) -58.64
PTIE's ROA (%) is ranked lower than
73% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. PTIE: -58.64 )
Ranked among companies with meaningful ROA (%) only.
PTIE' s ROA (%) Range Over the Past 10 Years
Min: -58.64  Med: -2.25 Max: 58.98
Current: -58.64
-58.64
58.98
ROC (Joel Greenblatt) (%) -7839.04
PTIE's ROC (Joel Greenblatt) (%) is ranked lower than
85% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. PTIE: -7839.04 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PTIE' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -38255.38  Med: -1726.78 Max: 731.79
Current: -7839.04
-38255.38
731.79
Revenue Growth (3Y)(%) -100.00
PTIE's Revenue Growth (3Y)(%) is ranked lower than
94% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. PTIE: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PTIE' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -100 Max: 132.2
Current: -100
0
132.2
EBITDA Growth (3Y)(%) 54.40
PTIE's EBITDA Growth (3Y)(%) is ranked higher than
91% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. PTIE: 54.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PTIE' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -18.3  Med: 18.2 Max: 54.4
Current: 54.4
-18.3
54.4
EPS Growth (3Y)(%) 57.10
PTIE's EPS Growth (3Y)(%) is ranked higher than
93% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. PTIE: 57.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PTIE' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -31.9  Med: 5.9 Max: 65.1
Current: 57.1
-31.9
65.1
» PTIE's 10-Y Financials

Financials (Next Earnings Date: 2017-03-01)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

PTIE Guru Trades in Q4 2015

Jim Simons 672,787 sh (+12.81%)
First Eagle Investment 5,684,510 sh (unchged)
Mario Gabelli 65,000 sh (unchged)
Charles Brandes 18,141 sh (-4.20%)
» More
Q1 2016

PTIE Guru Trades in Q1 2016

Charles Brandes 37,719 sh (+107.92%)
Jim Simons 726,987 sh (+8.06%)
Mario Gabelli 65,000 sh (unchged)
First Eagle Investment 5,684,510 sh (unchged)
» More
Q2 2016

PTIE Guru Trades in Q2 2016

Charles Brandes 78,758 sh (+108.80%)
First Eagle Investment 6,602,658 sh (+16.15%)
Jim Simons 799,787 sh (+10.01%)
Mario Gabelli 65,000 sh (unchged)
» More
Q3 2016

PTIE Guru Trades in Q3 2016

Jim Simons 910,187 sh (+13.80%)
Mario Gabelli 65,000 sh (unchged)
First Eagle Investment 6,602,658 sh (unchged)
Charles Brandes 53,200 sh (-32.45%)
» More
» Details

Insider Trades

Latest Guru Trades with PTIE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:GBLX, OTCPK:BNHLF, NAS:VTGN, OTCPK:QBIO, NAS:ONCS, NAS:VICL, NAS:MIRN, NAS:CUR, NAS:HSGX, OTCPK:SARSD, NAS:MCUR, NAS:CLBS, NAS:CYTX, OTCPK:LVCLF, NAS:KTOV, OTCPK:RGRX, NAS:ICCC, NAS:RTTR, NAS:ORPN, NAS:THLD » details
Traded in other countries:PX9.Germany,
Pain Therapeutics Inc is a biopharmaceutical company that develops novel drugs. The Company has four drug candidates in clinical programs, including Remoxy, Oxytrex, PTI-202 and a novel radio-labeled monoclonal antibody to treat metastatic melanoma.

Pain Therapeutics Inc a Delaware corporation was incorporated in May 1998. The Company is a biopharmaceutical company that develops novel drugs. The Company has four drug candidates in clinical programs, including REMOXY, PTI-202, PTI-721 and a novel radio-labeled monoclonal antibody to treat metastatic melanoma. Its drug candidate is called REMOXY. REMOXY is a painkiller with a formulation designed to reduce potential risks of unintended use. REMOXY is a novel controlled-release oral capsule form of oxycodone in a viscous liquid formulation matrix that includes novel excipients. The Company owns all commercial rights to its pipeline of drug candidates in oncology and hematology. It relies on a limited number of third-party manufacturers to formulate, manufacture, fill, label, ship or store all of its drug candidates. The company's strategies include Focus on Clinical Development Stage Products. It currently retains commercialization rights to all of its technology and drug candidates in all markets and indications, except for REMOXY and certain other abuse-resistant drugs. The Company has an exclusive Development and License Agreement, or the Durect Agreement, with Durect Corporation, or Durect, to use a patented technology that forms the basis for certain drug candidates, including REMOXY. Companies that currently sell generic or proprietary opioid formulations include, but are not limited to, Roxane Laboratories, Purdue Pharma, Pfizer, Abbott Laboratories, Endo Pharmaceuticals, Teva Pharmaceuticals, Elkins-Sinn, Watson Laboratories, Ortho-McNeil Pharmaceutical and Forest Pharmaceuticals. The Company is subject to governmental regulations.

Ratios

vs
industry
vs
history
P/B 1.32
PTIE's P/B is ranked higher than
85% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. PTIE: 1.32 )
Ranked among companies with meaningful P/B only.
PTIE' s P/B Range Over the Past 10 Years
Min: 0.58  Med: 3.85 Max: 15.24
Current: 1.32
0.58
15.24
Shiller P/E 65.06
PTIE's Shiller P/E is ranked lower than
55% of the 58 Companies
in the Global Biotechnology industry.

( Industry Median: 48.79 vs. PTIE: 65.06 )
Ranked among companies with meaningful Shiller P/E only.
PTIE' s Shiller P/E Range Over the Past 10 Years
Min: 13.77  Med: 59.13 Max: 451
Current: 65.06
13.77
451
Current Ratio 10.25
PTIE's Current Ratio is ranked higher than
77% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. PTIE: 10.25 )
Ranked among companies with meaningful Current Ratio only.
PTIE' s Current Ratio Range Over the Past 10 Years
Min: 5.33  Med: 10.25 Max: 61.08
Current: 10.25
5.33
61.08
Quick Ratio 10.25
PTIE's Quick Ratio is ranked higher than
78% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. PTIE: 10.25 )
Ranked among companies with meaningful Quick Ratio only.
PTIE' s Quick Ratio Range Over the Past 10 Years
Min: 5.33  Med: 10.25 Max: 61.08
Current: 10.25
5.33
61.08

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.30
PTIE's 3-Year Average Share Buyback Ratio is ranked higher than
93% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. PTIE: -0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PTIE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -101.1  Med: -2.05 Max: 1.5
Current: -0.3
-101.1
1.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.38
PTIE's Price/Net Cash is ranked higher than
93% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.05 vs. PTIE: 1.38 )
Ranked among companies with meaningful Price/Net Cash only.
PTIE' s Price/Net Cash Range Over the Past 10 Years
Min: 1.08  Med: 4.11 Max: 30.22
Current: 1.38
1.08
30.22
Price/Net Current Asset Value 1.35
PTIE's Price/Net Current Asset Value is ranked higher than
92% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 5.53 vs. PTIE: 1.35 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PTIE' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.06  Med: 4.04 Max: 11.83
Current: 1.35
1.06
11.83
Price/Tangible Book 1.32
PTIE's Price/Tangible Book is ranked higher than
89% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. PTIE: 1.32 )
Ranked among companies with meaningful Price/Tangible Book only.
PTIE' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.02  Med: 3.94 Max: 11.59
Current: 1.32
1.02
11.59
Earnings Yield (Greenblatt) (%) -333.30
PTIE's Earnings Yield (Greenblatt) (%) is ranked lower than
98% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. PTIE: -333.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PTIE' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -333.3  Med: 17.4 Max: 1032.2
Current: -333.3
-333.3
1032.2

More Statistics

EPS (TTM) $ -0.38
Beta2.14
Short Percentage of Float3.77%
52-Week Range $0.51 - 3.00
Shares Outstanding (Mil)46.14

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 10 35 60
EPS ($) -0.45 -0.40 -0.50 -0.15
EPS w/o NRI ($) -0.45 -0.40 -0.50 -0.15
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for PTIE

Headlines

Articles On GuruFocus.com
Wednesday Pre-Market Insights: GEVO, WPZ, HDP, PTIE May 13 2015 
Eveillard's First Eagle Increases 2 Positions Sep 11 2014 
Morning Coffee: Real-Time Picks May 14 2014 
Pain Therapeutics Reports Operating Results (10-K) Feb 03 2011 
Pain Therapeutics Reports Operating Results (10-Q) Oct 29 2010 
Pain Therapeutics (PTIE) CEO & Chairman of the Board, 10% Owner Remi Barbier sells 50,000 Shares Oct 04 2010 
Pain Therapeutics (PTIE) CEO & Chairman of the Board, 10% Owner Remi Barbier sells 28,597 Shares Sep 08 2010 
Pain Therapeutics (ptie) CEO & Chairman of the Board, 10% Owner Remi Barbier sells 21,403 Shares Sep 02 2010 
Pain Therapeutics (PTIE) CEO & Chairman of the Board, 10% Owner Remi Barbier sells 22,391 Shares Aug 04 2010 
Pain Therapeutics Reports Operating Results (10-Q) Jul 29 2010 

More From Other Websites
PAIN THERAPEUTICS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Nov 18 2016
Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Pain... Nov 11 2016
Durect (DRRX) Exited Third Quarter with Strong Balance Sheet Nov 01 2016
PAIN THERAPEUTICS INC Financials Oct 29 2016
PAIN THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report Oct 26 2016
Pain Therapeutics reports 3Q loss Oct 20 2016
Pain Therapeutics reports 3Q loss Oct 20 2016
Pain Therapeutics Reports Q3 2016 Financial Results Oct 20 2016
PAIN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition Oct 20 2016
Pain Therapeutics Reports Q3 2016 Financial Results Oct 20 2016
Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Pain... Oct 11 2016
Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Pain... Oct 01 2016
Pain Therapeutics (PTIE) Enters Oversold Territory Sep 29 2016
Pain Therapeutics (PTIE) Down on CRL for Chronic Pain Drug Sep 28 2016
Durect Corp. (DRRX) Stock Tumbles on FDA Opioid Analgesic Drug Rejection Sep 26 2016
5 Big-Volume Stocks You Should Stay Away From -- Plus 2 to Buy Sep 26 2016
GW Pharmaceuticals (GWPH), Sally Beauty Holdings Inc. (SBH) & More: Why These Stocks Are Making... Sep 26 2016
For Pain Therapeutics CEO, 3 FDA Rejections Are Worth $23 Million Sep 26 2016
Is Pain Therapeutics an Incredible Momentum Stock? 3 Reasons Why PTIE Will Be Tough to Beat Sep 26 2016
Get ready. One of tech’s biggest darlings is in for a bumpy ride Sep 26 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)